Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

被引：0

作者：

Radek Lakomy

Alexandr Poprach

Zbynek Bortlicek

Bohuslav Melichar

Renata Chloupkova

Rostislav Vyzula

Milada Zemanova

Katerina Kopeckova

Marek Svoboda

Ondrej Slaby

Igor Kiss

Hana Studentova

Jaroslav Juracek

Ondrej Fiala

Jindrich Kopecky

Jindrich Finek

Ladislav Dusek

Karel Hejduk

Tomas Buchler

机构：

[1] Masaryk Memorial Cancer Institute and Masaryk University,Department of Comprehensive Cancer Care and Faculty of Medicine

[2] Masaryk University,Institute of Biostatistics and Analyses, Faculty of Medicine

[3] Department of Oncology,Department of Oncology

[4] Palacky University Medical School and Teaching Hospital,Department of Oncology

[5] First Faculty of Medicine,Department of Oncology

[6] Charles University and General University Hospital,Department of Oncology, First Faculty of Medicine

[7] Second Faculty of Medicine,undefined

[8] Charles University and Motol University Hospital,undefined

[9] Charles University and University Hospital,undefined

[10] Department of Oncology,undefined

[11] Hradec Králové University Hospital and Faculty of Medicine,undefined

[12] Charles University,undefined

[13] Hradec Králové,undefined

[14] Charles University and Thomayer Hospital,undefined

来源：

BMC Cancer | / 17卷

关键词：

Renal cell carcinoma; Therapy; Sunitinib; Sorafenib; Everolimus; Pazopanib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 187 条

[11]

Bracarda S(2003)CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176-181

[12]

Motzer RJ(2015)Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study BMC Cancer 15 303-847

[13]

Escudier B(2015)SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer Eur Urol 68 837-167

[14]

Tomczak P(2016)Real-world effectiveness of everolimus subsequent to different first targeted therapies for the treatment of metastatic renal cell carcinoma: synthesis of retrospective chart reviews Clin Genitourin Cancer 14 160-300

[15]

Hutson TE(2015)The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Lancet Oncol 16 293-e72

[16]

Michaelson MD(2014)Real-world outcomes in metastatic renal cell carcinoma: insights from a joint community-academic registry J Oncol Pract 10 e63-2772

[17]

Negrier S(2014)Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma J Clin Oncol 32 2765-1170

[18]

Mitchell AP(2011)Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors Eur Urol 60 1163-2142

[19]

Harrison MR(2013)Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort Eur J Cancer 49 2134-1823

[20]

Walker MS(2014)Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies PLoS One 9 1814-978

← 1 2 3 4 5 6 7 8 9 10 →